![Sam Jactel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Sam Jactel currently works as a Director at Hypercell Technologies, Inc.
Sam Jactel active positions
Companies | Position | Start |
---|---|---|
Hypercell Technologies, Inc.
![]() Hypercell Technologies, Inc. Packaged SoftwareTechnology Services Hypercell Technologies, Inc. has developed a proprietary point-of-care diagnostic technology platform that allows for the early identification and management of biological contaminants in the food chain, from production to transformation. The private company is based in Brookhaven, GA and was founded by Bruno Jactel, who has been the CEO since incorporation. Despite advances in vaccines and testing tools, production animal diseases still cost $10 billion in lost productivity and threaten the human population when animal diseases jump to the human species. Food-borne diseases impact 48 million Americans every year and cost the economy more than $55 billion/year. Hypercell's solution is as accurate as the gold standard PCR, 10x faster, and without expensive lab equipment. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Hypercell Technologies, Inc.
![]() Hypercell Technologies, Inc. Packaged SoftwareTechnology Services Hypercell Technologies, Inc. has developed a proprietary point-of-care diagnostic technology platform that allows for the early identification and management of biological contaminants in the food chain, from production to transformation. The private company is based in Brookhaven, GA and was founded by Bruno Jactel, who has been the CEO since incorporation. Despite advances in vaccines and testing tools, production animal diseases still cost $10 billion in lost productivity and threaten the human population when animal diseases jump to the human species. Food-borne diseases impact 48 million Americans every year and cost the economy more than $55 billion/year. Hypercell's solution is as accurate as the gold standard PCR, 10x faster, and without expensive lab equipment. | Technology Services |
- Stock Market
- Insiders
- Sam Jactel